Xspray Pharma AB (publ) (LON: 0GHZ)

Market Cap	91.02M
Revenue (ttm)	n/a
Net Income (ttm)	-18.98M
Shares Out	n/a
EPS (ttm)	-0.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	198
Average Volume	711
Open	41.50
Previous Close	n/a
Day's Range	40.75 - 41.50
52-Week Range	2.53 - 5.62
Beta	0.82
RSI	47.68
Earnings Date	Feb 12, 2025

About Xspray Pharma AB

Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company’s product candidates include Dasynoc, a trailblazer, under approval phase for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib, under pivotal studies for the treatment of chronic myeloid leukemia; XS008, based on axitinib, under development for treatment of kidney cancer; and XS00Y under development phase. It has p...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2003
• Employees: 26
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0GHZ

Financial Performance

Financial numbers in SEK